QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

NCT ID: NCT04326829

Last Updated: 2022-12-07

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 86 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-08
• Study Completion Date: 2023-07-31

Brief Summary

In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with QL1604 monotherapy.

Conditions

Advanced Malignant Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

QL1604 Injection

Group Type: EXPERIMENTAL

QL1604

Intervention Type: DRUG

QL1604, IV infusion

Interventions

QL1604

QL1604, IV infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF);

2. Age ≥ 18 years and ≤ 80 years when ICF is signed;

3. Histologically confirmed locally advanced or metastatic dMMR or MSI-H status colorectal carcinoma or other malignant solid tumors;

4. At least one measureable lesion as defined per RECIST Version (v) 1.1 ;

5. Subjects who have disease progression or intolerable reactions after the currently available standard anti-cancer treatment previously received or refused prior cancer therapy regimen(s) ;

6. Subjects must provide tumor tissues and blood samples for the determination of MSI, tumor mutational burden (TMB), PD-L1 expression level;

7. Eastern Cooperative Oncology Group performance status of 0 or 1;

8. Life expectancy of greater than 12 weeks;

9. Adequate hematologic and organ function;

10. Female subjects who are not pregnant or breastfeeding

11. Male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 120 days after last dose.

Exclusion Criteria

1. Known hypersensitivity to any monoclonal antibody, QL1604 and/or any of its excipients;

2. Subjects with known central nervous system (CNS) metastasis;

3. Active autoimmune disease that has required systemic treatment in past 2 years, replacement therapy is acceptable;

4. Subjects with major cardiovascular and cerebrovascular diseases;

5. Subjects with uncontrollable pleural effusion, pericardial effusion or ascites;

6. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug;

7. Subjects who have received surgery, radiotherapy, chemotherapy, targeted therapy, other anti-tumor treatments, or participating in other clinical studies is less than 4 weeks before the first administration of investigational product;

8. Subjects who have not recovered to CTC AE Grade 1 or better from related side effects of any prior antineoplastic therapy;

9. Received a live vaccine within 30 days of planned start of study medication;

10. Infection with human immunodeficiency virus (HIV), HAV, HBV and HCV;

11. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, cytotoxic lymphocyte associated protein-4 (CTLA-4), OX-40, CD137;

12. Known psychiatric or substance abuse disorders that would interfere with the requirements of the study;

13. History or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study, or investigators/sponsor consider the subjects are not suitable for this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fudan University Cancer Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Shunjiang Yu, CMO

Role: CONTACT

shunjiang.yu@qilu-pharma.com

0531-83129659

Weijian Guo, Professor

Role: CONTACT

021-64175590

Facility Contacts

Weijian Guo, Professor

Role: primary

021-64175590

Feng Bi, Professor

Role: primary

References

Bi F, Dong J, Jin C, Niu Z, Yang W, He Y, Yu D, Sun M, Wang T, Yin X, Zhang R, Chen K, Wang K, Wang Z, Li W, Zhang Z, Zhang H, Guo Q, Wang X, Han L, Zhang X, Shen W, Zhang L, Ying J, Wu M, Hu W, Li Z, Li X, Feng W, Zhang B, Li L, Kang X, Guo W. Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial. J Hematol Oncol. 2024 Nov 11;17(1):109. doi: 10.1186/s13045-024-01627-5.

Reference Type: DERIVED

PMID: 39529169 (View on PubMed)

Other Identifiers

QL1604-201

Identifier Type: -

Identifier Source: org_study_id